Watch ENTX. Know when insiders buy.
One email the day a filing lands. Free.
ENTX
Entera Bio Ltd.
2.84
+0.05 +1.79%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $491.7MP/E 8.1DIV YIELD —FCF YIELD -2.23%REV TTM $0 −100.0%NET INCOME −$17MNET CASH —52W 1.00 – 3.92SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$4.6M | −$7.3M | — | 0.14 | −$3.5M | $3K | −$3.5M | Aug 7 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$3.5M | −$3.5M | — | 0.07 | −$3.1M | $0 | −$3.1M | May 8 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$3M | −$3M | — | 0.07 | −$1.8M | $27K | −$1.9M | Mar 27 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$3.3M | −$3.2M | — | 0.07 | −$2.5M | $43K | −$2.5M | Nov 14 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$2.7M | −$2.7M | — | 0.06 | −$1.6M | $29K | −$1.7M | Aug 7 |
| Q1 2025 · Mar 31 | $42K | — | 0.0% | −$2.6M | −$2.6M | — | 0.06 | −$1.4M | $8K | −$1.4M | May 8 |
| Q4 2024 · Dec 31derived | $82K | — | 0.0% | −$2.3M | −$2.4M | — | 0.06 | −$1.5M | $3K | −$1.5M | Mar 27 |
| Q3 2024 · Sep 30 | $42K | — | 0.0% | −$3M | −$3M | — | 0.08 | −$2.2M | $0 | −$2.2M | Nov 14 |
| Q2 2024 · Jun 30 | $57K | — | 15.8% | −$2.2M | −$2.1M | — | 0.06 | −$1.3M | $0 | −$1.3M | Aug 8 |
| Q1 2024 · Mar 31 | $0 | — | — | −$2.1M | −$2M | — | 0.05 | −$1.9M | $0 | −$1.9M | May 9 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$2M | −$2M | — | 0.07 | −$2.6M | $5K | −$2.6M | Mar 28 |
| Q3 2023 · Sep 30 | $0 | — | — | −$2.4M | −$2.4M | — | 0.08 | −$1.5M | $0 | −$1.5M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $42K | 0.0% | −$11.5M | −$11.4M | -27235.7% | 0.25 | −$7.4M | $107K | −$7.5M | — | — |
| FY2024 · to Dec 31 | $181K | 5.0% | −$9.6M | −$9.5M | -5271.3% | 0.25 | −$6.8M | $3K | −$6.8M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$8.9M | −$8.9M | — | 0.31 | −$7.3M | $17K | −$7.3M | — | — |
| FY2022 · to Dec 31 | $134K | 24.6% | −$13M | −$13.1M | -9754.5% | 0.45 | −$12.5M | $47K | −$12.5M | — | — |
| FY2021 · to Dec 31 | $571K | 34.7% | −$12.2M | −$12.2M | -2134.3% | 0.47 | −$9.1M | $17K | −$9.1M | — | — |
| FY2020 · to Dec 31 | $365K | 17.8% | −$11.2M | −$11.2M | -3072.9% | 0.67 | −$10.6M | $53K | −$10.6M | — | — |
Every number comes from Entera Bio Ltd.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.